| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1030: Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | durvalumab (Imfinzi®) |
| Formulation | 50 mg/mL concentrate for solution for infusion |
| Reference number | 5302 |
| Indication | Treatment of (neoadjuvant and adjuvant) resectable non-small-cell lung cancer with chemotherapy (stages II and III) |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/11/2024 |
| NICE guidance | |